Anuncio • Jul 15
PROCEPT BioRobotics Corporation to Report Q2, 2026 Results on Aug 04, 2026 PROCEPT BioRobotics Corporation announced that they will report Q2, 2026 results After-Market on Aug 04, 2026 Anuncio • May 29
PROCEPT Biorobotics® Advances Prostate Cancer Program With WATER IV Study Enrollment Completion And Expanded IDE Approval PROCEPT BioRobotics announced two milestones in its WATER IV prostate cancer clinical program: completion of enrollment in the randomized WATER IV study evaluating Aquablation therapy versus radical prostatectomy, and FDA Investigational Device Exemption (IDE) approval for a second randomized protocol evaluating Aquablation therapy versus active surveillance. The first randomized WATER IV study (WATER IV RP) fully enrolled 280 planned patients and is the only FDA randomized study comparing Aquablation therapy to radical prostatectomy, the established surgical standard of care. Based on current timelines, the Company expects to present the WATER IV RP primary endpoint results at the American Urological Association (AUA) Annual Meeting in spring 2027. The second randomized study in the WATER IV clinical program (WATER IV AS) will enroll up to 333 patients globally and evaluate Aquablation therapy versus active surveillance in men with Grade Group 1 and 2 prostate cancer. WATER IV AS is designed to evaluate whether Aquablation therapy may provide an earlier treatment option for men on active surveillance before the disease progresses further. Patients will be followed for ten years, including biopsy assessment at one year and MRI-based whole gland evaluation at three years. Both randomized WATER IV protocols will follow patients for ten years and are designed to evaluate the long-term experience of men with prostate cancer. The studies will assess both disease control and quality-of-life outcomes over time, including the impact of treatment on urinary, sexual, and overall function. Ultrasound-guided, transurethral robotic waterjet resection of the prostate is designed to remove cancer, at-risk tissue, and any obstructive tissue resulting in more than 95% of the gland being resected leaving only the outer prostatic capsule intact. Anuncio • Apr 23
PROCEPT BioRobotics Corporation, Annual General Meeting, Jun 09, 2026 PROCEPT BioRobotics Corporation, Annual General Meeting, Jun 09, 2026. Location: htps:/meetnow.global/mr7c96h, United States Anuncio • Apr 10
PROCEPT BioRobotics Corporation to Report Q1, 2026 Results on Apr 29, 2026 PROCEPT BioRobotics Corporation announced that they will report Q1, 2026 results After-Market on Apr 29, 2026 Anuncio • Mar 23
PROCEPT BioRobotics Highlights Upgrade of Aquablation Therapy in European Association of Urology Guidelines PROCEPT BioRobotics highlighted the latest update to the European Association of Urology Guidelines for male lower urinary tract symptoms, which include an upgrade of Aquablation therapy to a strong recommendation as a surgical treatment option for men with benign prostatic hyperplasia. The updated guidelines now strongly recommend offering Aquablation therapy as an alternative to transurethral resection of the prostate for men with moderate-to-severe urinary symptoms due to benign prostatic hyperplasia, particularly for patients interested in preserving ejaculatory function. Guidelines are supported by outcomes from multiple clinical trials on Aquablation therapy, including WATER, a randomized trial against transurethral resection of the prostate, and WATER II trials demonstrating durable improvements in urinary symptoms and preservation of sexual and urinary function. The guidelines also now recognize evidence supporting Aquablation therapy across a broad range of prostate anatomies, including larger prostate glands, with additional evidence continuing to emerge from recently published studies such as WATER III, a randomized trial against laser enucleation in large glands. Recognition from the European Association of Urology adds to growing international clinical validation for Aquablation therapy, including support from health technology assessment bodies such as the National Institute for Health and Care Excellence in the United Kingdom supporting the routine use of Aquablation therapy within the NHS. PROCEPT BioRobotics manufactures the AQUABEAM and HYDROS Robotic Systems. The HYDROS Robotic System is the only AI-powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia that are independent of prostate size and shape or surgeon experience. PROCEPT BioRobotics has developed a significant and growing body of clinical evidence with approximately 250 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy. All surgical treatments have inherent and associated side effects. Anuncio • Mar 13
Procept Biorobotics Announces International Launch of the Hydros Robotic System, Expanding Global Access to Ai-Enabled Aquablation Therapy PROCEPT BioRobotics announced the international expansion of the HYDROS Robotic System, the company’s next-generation platform for delivering Aquablation therapy to treat benign prostatic hyperplasia (BPH). HYDROS is the first AI-enabled robotic platform designed specifically for the treatment of BPH with Aquablation therapy. Leveraging AI-interpreted, real-time ultrasound imaging and advanced image-guided treatment planning, the system enables surgeons to deliver personalized, anatomy-specific therapy with robotic precision and reproducibility. The platform is designed to support scalable adoption across care settings while maintaining consistent procedural execution. Aquablation therapy offers a complete solution for men living with BPH. A robust body of clinical evidence continues to demonstrate Aquablation delivers durable symptom relief while preserving sexual and urinary function, outcomes that are critically important to patients. The HYDROS Robotic System brings AI-enabled, real-time ultrasound-guidance and robotic assisted treatment planning to NICE-recommended Aquablation therapy in the UK, supporting precise, anatomy-specific treatment. Aquablation with HYDROS enables durable symptom relief and preservation of quality-of-life outcomes, including sexual and urinary function and meaningfully expands surgical choice for men living with BPH. Aquablation therapy is the first and only ultrasound guided, robotic-assisted, heat-free waterjet for the treatment of BPH. The system’s real-time ultrasound imaging provides the surgeon with a multi-dimensional view of the prostate enabling personalized treatment planning tailored to each patient’s unique anatomy. The surgeon can specify which areas of the prostate to remove while preserving the anatomy that controls erectile function, ejaculatory function and continence. Once the treatment plan is mapped by the surgeon, the predictable robotic-assisted execution enables prostate tissue to be removed in a precise, targeted and controlled fashion. All surgical treatments have inherent and associated side effects. Anuncio • Mar 06
Procept Biorobotics Corporation Appoints Daniel Puckett Board and Audit Committee Member, Effective March 5, 2026 On March 5, 2026, the board of directors (the “Board”) of PROCEPT BioRobotics Corporation (the “Company”) approved (i) an increase in the size of the Board from eight members to nine members, (ii) appointed Mr. Daniel Puckett as a new member of the Board to fill the resulting vacancy, and (iii) appointed Mr. Puckett as a member of the Audit Committee of the Board, with such appointment effective immediately. Mr. Puckett was classified as a Class III director, and his initial term will expire at the Company’s 2027 annual meeting of stockholders and until his successor has been elected and qualified, or until his earlier death, resignation or removal. The Board has determined that Mr. Puckett is an “independent director” as defined under the applicable rules and regulations of the Securities and Exchange Commission (“SEC”) and the listing requirements and rules of the Nasdaq stock market, and, accordingly, determined he is qualified to serve on the Audit Committee of the Board. Mr. Puckett previously served as Chief Financial Officer of Shockwave Medical Inc., a leading medical device company that develops treatments for cardiovascular disease, from April 2016 until his retirement in February 2024. Prior to Shockwave Medical, he served as Chief Financial Officer of Counsyl Inc., from June 2015 to April 2016 and as Chief Financial Officer of Ariosa Diagnostics Inc. from 2011 to June 2015. Earlier in his career, Mr. Puckett held senior finance and operations roles at Forest Laboratories Inc. and its subsidiary Cerexa Inc., as well as at Affymetrix Inc. and AOL Inc. He received an M.B.A. from the University of San Francisco and a B.A. in Accounting from Washington State University. Anuncio • Jan 27
PROCEPT BioRobotics Corporation to Report Q4, 2025 Results on Feb 24, 2026 PROCEPT BioRobotics Corporation announced that they will report Q4, 2025 results at 4:00 PM, Central European Standard Time on Feb 24, 2026 Anuncio • Nov 05
Procept Biorobotics Corporation Reiterates Earnings Guidance for 2025 and Provides Revenue Guidance for 2026 PROCEPT BioRobotics Corporation reiterated earnings guidance for 2025 and Provides revenue guidance for 2026. The Company reiterates revenue for the full year 2025 to be approximately $325.5 million, which represents 45% growth over the Company’s prior year revenue.
The Company projects revenue for the full year 2026 to be in the range of $410 to $430 million, which represents growth of 26% to 32% over the Company’s 2025 revenue guidance range. Anuncio • Oct 16
PROCEPT BioRobotics Corporation to Report Q3, 2025 Results on Nov 04, 2025 PROCEPT BioRobotics Corporation announced that they will report Q3, 2025 results After-Market on Nov 04, 2025 Anuncio • Aug 07
PROCEPT BioRobotics Corporation Increases Earnings Guidance for the Full Year 2025 PROCEPT BioRobotics Corporation increased earnings guidance for the full year 2025. The company projected revenue for the full year 2025 revenue to be approximately $325.5 million, which represents 45% growth over the company’s prior year revenue. This compares to previous revenue guidance of $323.0 million. The company expects net loss for the full year 2025 to be $83,500,000. Anuncio • Jul 23
PROCEPT BioRobotics Corporation Completes WATER IV Trial Procedures for Prostate Cancer with Aquablation Therapy PROCEPT BioRobotics Corporation announced that three prostate cancer procedures in the WATER IV Prostate Cancer (PCa) Trial were successfully completed in an Ambulatory Surgery Center (ASC) using Aquablation®? therapy by Dr. Rahul Mehan of East Valley Urology in Scottsdale, Arizona. WATER IV PCa is a U.S. FDA investigational device exemption (IDE) approved clinical study comparing Aquablation®? therapy and radical prostatectomy for the treatment of localized prostate cancer. The study will evaluate and compare the safety and efficacy of Aquablation therapy and radical prostatectomy For men with Grade Group 1 to 3 localized prostate cancer. Aquablation therapy is an image-guided, minimally invasive surgery that aims to resect (remove) diagnosed cancer and most of the prostate using a robotically-controlled waterjet. Radical prostatectomy is a traditional surgery that removes the entire prostate along with some surrounding tissue. A surgical robot is often used to perform the radical prostatectomy surgery. Anuncio • Jul 22
PROCEPT BioRobotics Corporation to Report Q2, 2025 Results on Aug 06, 2025 PROCEPT BioRobotics Corporation announced that they will report Q2, 2025 results at 4:00 PM, Central European Standard Time on Aug 06, 2025 Anuncio • Apr 25
PROCEPT BioRobotics Corporation Increases Revenue Guidance for the Year 2025 PROCEPT BioRobotics Corporation increased revenue guidance for the year 2025. The Company projects revenue for the full year 2025 to be $323.0 million, which represents 44% growth over the Company’s prior year revenue. This compares to previous revenue guidance of $320.0 million. Anuncio • Apr 12
PROCEPT BioRobotics Corporation, Annual General Meeting, Apr 25, 2025 PROCEPT BioRobotics Corporation, Annual General Meeting, Apr 25, 2025. Anuncio • Mar 25
PROCEPT BioRobotics Corporation Announces WATER III Randomized-Controlled Trial Results PROCEPT BioRobotics® Corporation announced its Aquablation therapy was evaluated in the independent, investigator-initiated WATER III trial. This study compared Aquablation therapy to laser enucleation for treating large prostates, with results presented in the prestigious Game-Changer session at the European Association of Urology (EAU) 2025 Annual Congress in Madrid, Spain. WATER III is an international, prospective, multicenter study comparing Aquablation therapy to laser enucleation in prostate sizes 80-180mL. The study treated 186 men between December 2020 and September 2024 and reported three-month primary safety and efficacy endpoints and will subsequently follow patients to five years. The three-month results demonstrated that Aquablation therapy delivered substantially similar symptom relief while showing significantly lower rates of ejaculatory dysfunction (14.8% vs. 77.1%) and stress incontinence (0% vs. 9.1%) compared to laser enucleation. Additionally, the procedural transfusion rate in the Aquablation therapy arm was 0%. These findings demonstrate that modern Aquablation therapy techniques are both safe and highly reproducible in managing bleeding risk. These results add to Aquablation therapy’s robust clinical foundation, which include the randomized WATER study (Aquablation therapy vs. TURP in 30-80 mL prostates) with five-year results, WATER II (Aquablation therapy in large prostates 80-150 mL) with five-year results, coupled with over 150 peer-reviewed publications. The growing body of clinical evidence, including multiple randomized clinical studies, demonstrate Aquablation therapy is a globally, reproducible procedure with the potential to become the BPH standard of care for all prostate sizes. 
